Search Results - "Polidori, David"

How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake by Polidori, David, Sanghvi, Arjun, Seeley, Randy J., Hall, Kevin D.

“…Objective To quantify the feedback control of energy intake in response to long‐term covert manipulation of energy balance in free‐living humans. Methods A…”
Get full text

Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content by Utzschneider, Kristina M, Kahn, Steven E, Polidori, David C

“…Abstract Context Total insulin clearance is decreased in nonalcoholic fatty liver disease (NAFLD), but the relationship between liver fat and hepatic insulin…”
Get full text

Hepatic but Not Extrahepatic Insulin Clearance Is Lower in African American Than in European American Women by Piccinini, Francesca, Polidori, David C, Gower, Barbara A, Bergman, Richard N

“…African Americans (AAs) tend to have higher plasma insulin concentrations than European Americans (EAs); the increased insulin concentrations have been…”
Get full text

Hepatic and Extrahepatic Insulin Clearance Are Differentially Regulated: Results From a Novel Model-Based Analysis of Intravenous Glucose Tolerance Data by Polidori, David C, Bergman, Richard N, Chung, Stephanie T, Sumner, Anne E

“…Insulin clearance is a highly variable and important factor that affects circulating insulin concentrations. We developed a novel model-based method to…”
Get full text

Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics by Smith, Gordon I, Polidori, David C, Yoshino, Mihoko, Kearney, Monica L, Patterson, Bruce W, Mittendorfer, Bettina, Klein, Samuel

“…BACKGROUNDInsulin is a key regulator of metabolic function. The effects of excess adiposity, insulin resistance, and hepatic steatosis on the complex…”
Get full text

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models by Liang, Yin, Arakawa, Kenji, Ueta, Kiichiro, Matsushita, Yasuaki, Kuriyama, Chiaki, Martin, Tonya, Du, Fuyong, Liu, Yi, Xu, June, Conway, Bruce, Conway, Jamie, Polidori, David, Ways, Kirk, Demarest, Keith

“…Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type 2 diabetes mellitus (T2DM)…”
Get full text

Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants by Devineni, Damayanthi, PhD, Vaccaro, Nicole, BS, Polidori, David, PhD, Rusch, Sarah, MSc, Wajs, Ewa, MD, PhD

“…Abstract Background Many patients with type 2 diabetes mellitus (T2DM) also have hypertension, which is commonly treated with thiazide diuretics, including…”
Get full text

Response to Letter to the Editor: “Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content” by Utzschneider, Kristina M, Kahn, Steven E, Polidori, David C

Get full text

Dissection of hepatic versus extra‐hepatic insulin clearance: Ethnic differences in childhood by Piccinini, Francesca, Polidori, David C., Gower, Barbara A., Fernandez, Jose R., Bergman, Richard N.

“…Aims Adult African American (AA) women have one third of the hepatic insulin clearance of European American (EA) women. This lower hepatic (but not…”
Get full text

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus by Rosenthal, Norm, Meininger, Gary, Ways, Kirk, Polidori, David, Desai, Mehul, Qiu, Rong, Alba, Maria, Vercruysse, Frank, Balis, Dainius, Shaw, Wayne, Edwards, Robert, Bull, Scott, Di Prospero, Nicholas, Sha, Sue, Rothenberg, Paul, Canovatchel, William, Demarest, Keith

“…The sodium glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin is a novel treatment option for adults with type 2 diabetes mellitus (T2DM). In patients…”
Get full text

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes by Sha, Sue, Devineni, Damayanthi, Ghosh, Atalanta, Polidori, David, Hompesch, Marcus, Arnolds, Sabine, Morrow, Linda, Spitzer, Heike, Demarest, Keith, Rothenberg, Paul

“…This randomized, double-blind, placebo-controlled, single and multiple ascending-dose study evaluated the pharmacodynamic effects and safety/tolerability of…”
Get full text

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans by Fourie, Anne M., Cheng, Xiaoli, Chang, Leon, Greving, Carrie, Li, Xinyi, Knight, Beverly, Polidori, David, Patrick, Aaron, Bains, Trpta, Steele, Ruth, Allen, Samantha J., Patch, Raymond J., Sun, Chengzao, Somani, Sandeep, Bhandari, Ashok, Liu, David, Huie, Keith, Li, Shu, Rodriguez, Michael A., Xue, Xiaohua, Kannan, Arun, Kosoglou, Teddy, Sherlock, Jonathan P., Towne, Jennifer, Holland, M. Claire, Modi, Nishit B.

“…The interleukin (IL)-23 pathway is a pathogenic driver in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Currently, no oral therapeutics…”
Get full text

A long‐acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate model by Zheng, Songmao, Polidori, David, Wang, Yuanping, Geist, Brian, Lin‐Schmidt, Xiefan, Furman, Jennifer L., Nelson, Serena, Nawrocki, Andrea R., Hinke, Simon A.

“…Growth Differentiation Factor‐15 (GDF15) is a circulating polypeptide linked to cellular stress and metabolic adaptation. GDF15's half‐life is ~3 h and…”
Get full text

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport by Mudaliar, Sunder, Polidori, David, Zambrowicz, Brian, Henry, Robert R.

“…Type 2 diabetes is a chronic disease with disabling micro- and macrovascular complications that lead to excessive morbidity and premature mortality. It affects…”
Get full text

Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants by Devineni, Damayanthi, PhD, Polidori, David, PhD, Curtin, Christopher, BSc, Stieltjes, Hans, MSc, Tian, Hong, PhD, Wajs, Ewa, MD, PhD

“…Abstract Purpose Canagliflozin, an orally active selective inhibitor of sodium glucose cotransporter 2, has been approved in several countries for the…”
Get full text

GNSS Radio Frequency Interference Monitoring from LEO Satellites: An In-Laboratory Prototype by Troglia Gamba, Micaela, Polidori, Brendan David, Minetto, Alex, Dovis, Fabio, Banfi, Emilio, Dominici, Fabrizio

“…The disruptive effect of radio frequency interference (RFI) on global navigation satellite system (GNSS) signals is well known, and in the last four decades,…”
Get full text

Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects by Chen, Xia, MD, Hu, Pei, MD, Vaccaro, Nicole, BS, Polidori, David, PhD, Curtin, Christopher R., BS, Stieltjes, Hans, MSc, Sha, Sue, MD, PhD, Weiner, Sveta, MS, Devineni, Damayanthi, PhD

“…Abstract Purpose Canagliflozin, an orally active sodium–glucose cotransporter 2 inhibitor, is approved in many countries as an adjunct to diet and exercise to…”
Get full text

Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants by Devineni, Damayanthi, Polidori, David, Curtin, Christopher R, Murphy, Joseph, Wang, Shean-Sheng, Stieltjes, Hans, Wajs, Ewa

“…Assess the steady-state pharmacokinetics, pharmacodynamics and safety of once-daily (q.d.) versus twice-daily (b.i.d.) dosing with canagliflozin at the same…”
Get full text

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes by Sha, Sue, Devineni, Damayanthi, Ghosh, Atalanta, Polidori, David, Hompesch, Marcus, Arnolds, Sabine, Morrow, Linda, Spitzer, Heike, Demarest, Keith, Rothenberg, Paul

“…This randomized, double-blind, placebo-controlled, single and multiple ascending-dose study evaluated the pharmacodynamic effects and safety/tolerability of…”
Get full text

Alteration of the Glucagon Axis in GPR120 (FFAR4) Knockout Mice by Suckow, Arthur T., Polidori, David, Yan, Wen, Chon, Suhyoun, Ma, Jing Ying, Leonard, James, Briscoe, Celia P.

“…GPR40 (FFAR1) and GPR120 (FFAR4) are G-protein-coupled receptors (GPCRs) that are activated by long chain fatty acids (LCFAs). GPR40 is expressed at high…”
Get full text